The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

@article{Mcmurray2006TheEO,
  title={The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).},
  author={J J V Mcmurray and Scott Solomon and Karen S. Pieper and Shelby Reed and Jean Lucien Rouleau and Eric Jose Velazquez and Harvey Douglas White and Jonathan G. Howlett and Karl Swedberg and Aldo Pietro Maggioni and Lars Valeur K\ober and Frans Van de Werf and Rob Califf and Marc Pfeffer},
  journal={Journal of the American College of Cardiology},
  year={2006},
  volume={47 4},
  pages={726-33}
}
OBJECTIVES We attempted to compare the effect of an angiotensin-converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on atherosclerotic events. BACKGROUND Angiotensin-converting enzyme inhibitors and ARBs interrupt the renin-angiotensin system by distinct mechanisms. It is not clear whether ARBs reduce atherosclerotic events such as myocardial infarction (MI) like ACE inhibitors. This evidence gap may reflect the nature of the studies conducted, to date. Placebo-controlled… CONTINUE READING
36 Citations
28 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Granger CB, et al., for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

  • MA Pfeffer, K Swedberg
  • 2003
1 Excerpt

Similar Papers

Loading similar papers…